New conservative treatment options in functional urology

Poster Session 80

Monday 19 March
14:00 - 15:30

Location: Blue Area, Room 3 (Level 0)
Chairs: T.J. Greenwell, London (GB)
       H. Kakizaki, Asahikawa (JP)
       G. Van Koeveringe, Maastricht (NL)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

1082

Vibegron, a novel potent and selective β3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: A randomized, double-blind, placebo-controlled phase 3 study

By: Yoshida M. 1, Takeda M. 2, Goto M. 3, Nagai S. 4, Kurose T. 4
1National Center For Geriatrics and Gerontology, Dept. of Urology, Obu, Aichi, Japan,
2University of Yamanashi, Graduate School of Medical Sciences,, Dept. of Urology, Chuo,
Yamanashi, Japan,
3Nagoya University Graduate School of Medicine, Dept. of Urology,
Nagoya, Japan,
4Kyorin Pharmaceutical Co., Ltd., Clinical Development Center, Tokyo,
Japan

1083

Natural treated history of urinary urgency: A 21-year follow-up of Tampere Aging Male Urologic Study (TAMUS)

By: Åkerla J. 1, Pesonen J. 2, Hämäkinen J. 3, Koskimäki J. 4, Tammela T. 4, Auvinen A. 5
1Central Finland Central Hospital, Dept. of Surgery, Jyväskylä, Finland,
2Päijät-Häme Central Hospital, Dept. of Surgery, Lahti, Finland,
3Turku University Hospital, Dept. of Urology, Turku, Finland,
4Tampere University Hospital, Dept. of Urology, Tampere, Finland,
5University of Tampere, Faculty of Social Sciences, Tampere, Finland

1084

Long term compliance with repeated botulinum toxin A injections in patients with neurogenic detrusor overactivity after spinal cord injury

By: Hebert K. 1, Klarskov N. 2, Bagi P. 1, Biering-Sørensen F. 3, Elmelund M. 3
1Rigshospitalet, University of Copenhagen, Dept. of Urology, Copenhagen, Denmark,
2Herlev and Gentofte Hospital, University of Copenhagen, Dept. of Obstetrics , Herlev,
Denmark,
3Rigshospitalet, University of Copenhagen, Clinic for Spinal Cord Injuries,
Copenhagen, Denmark

1085

Mirabegron integrated database: Do safety and tolerability differ by sex?

By: Staskin D.R. 1, Herschorn S. 2, Wagg A. 3, Heesakkers J. 4, Cardozo L. 5, Milsom I. 6, Chapple C. 7, Cruz F. 8, Stoelzel M. 9, Schermer C. 10, Siddiqui E. 11
1St. Elizabeth's Medical Center, Dept. of Urology, Brighton, United States of America, 2University of Toronto, Dept. of Urology, Toronto, Canada, 3University of Alberta, Dept. of Geriatric Medicine, Edmonton, Canada, 4Radboudumc University Medical Centre, Dept. of Urology, Nijmegen, Netherlands, The, 5King’s College Hospital, Dept. of Urogynaecology, London, United Kingdom, 6Institute of Clinical Sciences, Dept. of Obstetrics and Gynecology, Gothenburg, Sweden, 7Royal Hallamshire Hospital, Dept. of Urology, Sheffield, United Kingdom, 8Hospital S João and Faculty of Medicine, Dept. of Urology, Porto, Portugal, 9Astellas Pharma Europe, Dept. of Data Science, Leiden, Netherlands, The, 10Astellas Pharma, Dept. of Medical Affairs, Northbrook, United States of America, 11Astellas Pharma, Dept. of Global Medical Affairs, Chertsey, United Kingdom

1086

Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada

By: Elterman D., Shepherd S., Minhas R., Tadrous M., Gomes T.
1University Health Network - Toronto Western Hospital, Dept. of Urology, Toronto, Canada, 2McMaster University, Dept. of Health Research Methods, Evidence and Impact, Hamilton, Canada, 3University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, Canada, 4University of Toronto, The Leslie Dan Faculty of Pharmacy, Toronto, Canada

1087

Comparative of efficiency and safety of medicinal product Imidafenacin and tolterodine for treatment of overactive bladder

By: Sharvadze G., Mukhametshina E., Samsonov M.
R-Pharm Group, Medical Department, Moscow, Russia

1088

Anticholinergic burden with antimuscarinics in elderly Japanese patients receiving overactive bladder medication: A nationwide real-world analysis

1National Center for Geriatrics and Gerontology, Dept. of Urology, Obu, Japan, 2Astellas Pharma Inc., Medical Affairs, Tokyo, Japan, 3Astellas Pharma Inc., Real World Informatics and Analytics, Tokyo, Japan, 4Astellas Pharma US Inc., Real World Informatics and Analytics, Northbrook, Illinois, United States of America, 5Astellas Pharma Inc., Development, Tokyo, Japan

1089

Urinary function improves in hypogonadal men with moderate International Prostate Symptom Score (IPSS) treated for up to 10 years with testosterone in comparison to untreated controls

By: Haider K.S., Haider A., Doros G., Traish A.
1Private Urology Practice, Dept. of Urology, Bremerhaven, Germany, 2Boston University School of Public Health, Dept. of Epidemiology and Statistics, Boston, United States of America, 3Boston University School of Medicine, Dept. of Biochemistry and Urology, Boston, United States of America

1090

Effect of imipramine on urethral opening pressure - a randomized, double-blind, placebo-controlled crossover study in healthy women
1091
The management of nocturia and nocturnal polyuria in the daily practice: Results of a Dutch survey

By: Rahnama'i M.S., Vrijens D., Marcelissen T.
Maastricht University Medical Centre, Dept. of Urology, Maastricht, Netherlands, The Netherlands

1092
Comparative efficacy and safety of fixed dose combination of solifenacin+tamsulosin between treatment-naive patients and patients crossing over from prior alpha-blocker and/or antimuscarinic therapy

By: Georgopoulos P., Apostolidis I., Papaefstathiou E., Kalaitzi M., Ioannidis I-E., Apostolidis A.
Aristotle University of Thessaloniki, Dept. of Urology, Thessaloniki, Greece

1093
Real life data on mirabegron in neurogenic bladder dysfunction

By: Soebadi M.A., Hakim L., Van Der Aa F., De Ridder D.
Dr Soetomo Hospital Universitas Airlangga, Dept. of Urology, Surabaya, Indonesia, University Hospitals KU Leuven, Dept. of Urology, Leuven, Belgium

1094
Clinical outcomes of second-line treatments cycling in refractory wet overactive bladder patients before switching to a third-line therapy: A real world observational study

By: Giannantoni A., Gubbiotti M., Rossi De Vermandois J.A., Quadrini F., Cagini R., Mearini E.
University of Perugia, Dept. of Surgical and Biomedical Sciences, Perugia, Italy

1095
The health-care seeking prevalence of lower urinary tract symptoms in an adult cohort - a nationwide, population-based observational study, 2005-2012

Cardinal Tien Hospital, Division of Urology, Dept. of Surgery, New Taipei City, Taiwan, National Yang-Ming University, Institute of Health and Welfare Policy, Taipei, Taiwan, National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan

1096
Quality of life in older patients with overactive bladder treated with mirabegron in routine clinical practice: Secondary analysis of a pan-European non-interventional study (BELIEVE)

By: Foley S., Choudhury N., Huang M., Stari A., Nazir J., Freeman R.
Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom, Astellas Pharma Europe Ltd, Medical Affairs, EMEA, Chertsey, United Kingdom, Astellas Pharma Europe
Summary
T.J. Greenwell, London (GB)